Overview

Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients

Status:
Completed

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the therapeutic equivalence between the two arms of treatment in virological and immunological response after 48 weeks and to evaluate the presence of side effects during the follow-up period.

Phase:

Phase 3

Details

Lead Sponsor:

Germans Trias i Pujol Hospital

Collaborators:

Fundacio Lluita Contra la SIDA
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Treatments:

Abacavir
Dideoxynucleosides
Efavirenz
Lamivudine